	US 12,357,604 B2
	Topical formulations of cannabinoids and use thereof in the treatment of pain
Hayes Wong, North Vancouver (CA); Sazzad Hossain, Richmond (CA); Brian Cairns, Vancouver (CA); Karen Ann Long, Vancouver (CA); and Alexandra Mancini, West Vancouver (CA)
Assigned to INMED PHARMACEUTICALS INC., Vancouver (CA)
Appl. No. 16/649,119
Filed by INMED PHARMACEUTICALS INC., Vancouver (CA)
PCT Filed Sep. 21, 2018, PCT No. PCT/CA2018/051194 § 371(c)(1), (2) Date Mar. 19, 2020, PCT Pub. No. WO2019/056123, PCT Pub. Date Mar. 28, 2019.
Claims priority of provisional application 62/562,166, filed on Sep. 22, 2017.
Prior Publication US 2020/0289458 A1, Sep. 17, 2020
Int. Cl. A61K 31/352 (2006.01); A61K 31/01 (2006.01); A61K 31/045 (2006.01); A61K 31/05 (2006.01); A61K 31/08 (2006.01); A61K 31/343 (2006.01); A61K 31/397 (2006.01); A61K 31/415 (2006.01); A61K 31/4178 (2006.01); A61K 45/06 (2006.01); A61K 47/24 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 31/01 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/08 (2013.01); A61K 31/343 (2013.01); A61K 31/397 (2013.01); A61K 31/415 (2013.01); A61K 31/4178 (2013.01); A61K 45/06 (2013.01); A61K 47/24 (2013.01)]

7 Claims

1. A pharmaceutical composition for treating pain, the pharmaceutical composition comprising:

a. a therapeutically effective quantity of a mixture of one or more cannabidiols and cannabinol in a ratio of 5:1 μM,

wherein the therapeutically effective quantity of the mixture is an amount that induces no or substantially no psychoactive effect when administered by topical administration and is sufficient to reduce or reverse pain and/or central sensitization; and

b. at least one pharmaceutically acceptable carrier for topical administration of the pharmaceutical composition, wherein the pharmaceutical carrier comprises caprylocaproyl polyoxy-8 glycerides, poloxamer 407, lecithin, and isopropyl palmitate, and

wherein the pharmaceutical composition is a topical formulation.